In terms of genetic mutations, in the observation group, one case with mutations in SF3B1, ASXL1, RUNX1, and EZH2 at the time of initial diagnosis and one case with mutations in TET2 and ASXL1 were converted to acute myelogenous leukemia soon after treatment with demethylating therapy and had a poor prognosis, in line with the results of Venable et al.’s study [20]. The gene discussed is SF3B1; the disease is acute myeloid leukemia.